



**VIJAYA
DIAGNOSTIC
CENTRE** ®

September 11, 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Strategic Acquisition / Execution of Business Transfer Agreement (BTA)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our earlier disclosure dated **September 11, 2026** regarding the approval/execution of the Business Transfer Agreement (BTA) for the 100% acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Assam on a slump sale basis from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited - Hexagon Research Private Limited JV), we are enclosing herewith a copy of the **Investor Presentation** detailing the rationale, financial highlights, and strategic synergy of the said acquisition.

Please take the information on record.

Thanking you,
For **Vijaya Diagnostic Centre Limited**

Narasimha Raju K A
Chief Financial Officer

Encl.: As Above



**VIJAYA
DIAGNOSTIC
CENTRE**

Acquisition of Integrated Diagnostic Business (Arya Wellness Centre) in Guwahati, Assam

September 11, 2026

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Business Overview

- Leading **B2C focused integrated diagnostic centre in Guwahati, Assam** serving entire **North-East market**
- Founded in **2021** as a **Joint Venture / AOP** between **North Eastern Medical Research Institute Ltd. (NEMRIL)**, which operates Arya Hospital, a leading multispecialty hospital in Guwahati, and **Hexagonal Research Pvt. Ltd. (HRPL)**, representing a group of reputed doctors.
- The **AOP** operates under the brand **“Arya Wellness Centre”** from a single, well-equipped facility strategically located on **GS Road, Guwahati’s key healthcare hub**, and supported by a **central reference laboratory**
- Business Mix:** Adv Radiology: 35%, Basic Radiology: 9%, Adv Pathology: 16%, Basic Pathology: 40%
- 85% + business** comes from B2C due to strong pedigree of doctors both in pathology and radiology

Modalities



FY26 Financial Performance

INR 260 Mn

Revenue from Operations ⁽¹⁾

INR 56 Mn | 21.4%

EBITDA ⁽²⁾ | EBITDA Margin %

INR 25 Mn | 9.5%

PAT ⁽³⁾ | PAT Margin %

Key Metrics



44% | 56%

Radiology | Pathology

200+

Daily FF



1 | 1

Centre | Lab

7%

Home Collection %





Dr. Bijoya Goswami (NEMRIL)

- ✓ 40+ years of entrepreneurial experience
- ✓ Founder & MD, Arya Hospital



Dr. Anup Das (HRPL)

- ✓ 20+ years of experience in Histopathology and Cytology
- ✓ MD in Pathology – **AIIMS, Delhi**



Dr. Pratap Kakati (HRPL)

- ✓ 20+ yrs of post MD experience
- ✓ MD in Radiology – **PGIMER, Chandigarh**



Dr. Palash Jyoti Das (HRPL)

- ✓ 20+ yrs of post MD experience
- ✓ MD & SR in Interventional Radiology – **PGIMER, Chandigarh**



Dr. Anil Kumar Agarwala (HRPL)

- ✓ 20+ yrs of experience
- ✓ Diploma in Clinical Pathology (DCP) from Assam Medical College & Hospital (AMCH)

Transaction Consideration and Potential Timelines for the Closure

Transaction at a Glance

TRANSACTION CONSIDERATION

~₹46 Cr

100%

Business acquisition

**Slump Sale
(BTA)**

Transaction structure

**~8-9x
EBITDA⁽¹⁾**

Valuation

**Internal
Accruals**

Consideration

Indicative Transaction Timelines

10 Sep 2026

~Nov / Dec 2026⁽²⁾

BTA Signing

Transaction
announced

**CP Satisfaction
& Transition**

CP Completion

**Business Transfer
/ Closing**

Completion and
operational handover

The acquisition is EPS accretive right from the onset and provides us with an established and profitable operating base in Guwahati while maintaining our focus on capital efficiency and return thresholds



- 1** Guwahati is a natural extension to our growing presence in West Bengal and provides us with an attractive gateway to the wider North East region
- 2** Provides immediate access to established operating platform with existing infrastructure, clinical capabilities & recognized local presence
- 3** Specializes in High-End Imaging, Interventional Procedures and Histopathology work with an established B2C customer base
- 4** Located strategically at the heart of Healthcare Infrastructure of Guwahati
- 5** Reputed & Renowned Clinicians across pathology & radiology driving B2C business
- 6** Healthy Financials with ~80% Gross Margin and ~21% EBITDA margin ⁽¹⁾




Commenting on the acquisition, Ms. Suprita Reddy, Managing Director & CEO, Vijaya Diagnostic Centre Limited, said:

“Our entry into Guwahati represents another important milestone in Vijaya’s journey towards building a high-quality integrated diagnostics platform. Guwahati is a natural strategic extension of our growing presence in West Bengal and provides us with an attractive gateway to the North-East.

Arya Wellness Centre has been built on an ethos that closely aligns with Vijaya’s philosophy of delivering high-quality diagnostics with a strong focus on patient experience and convenience. It is a unique asset in Guwahati with a balanced mix of advanced and basic pathology and radiology services, making it a strategically attractive asset for us.

We believe this acquisition provides Vijaya with a strong platform to establish a meaningful presence in Assam and progressively expand across the North-Eastern region. Over time, we intend to build upon this base through a calibrated expansion strategy.”

Expanding our Footprint with Entry into North-East



Provides Vijaya with an established operating platform in a strategically synergistic market, strengthening our Eastern India presence and creating a strong foundation for expansion across the North-East



**VIJAYA
DIAGNOSTIC
CENTRE**

Thank You

For further information please contact:

Mr. Dhiren Gala

Head - Investor Relations & Corporate Development

+91 90598 93206

dhiren.g@vijayadiagnostic.in

ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.